Shares of MBX Biosciences, Inc. (NASDAQ:MBX – Get Free Report) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $46.01 and last traded at $43.9450, with a volume of 201790 shares trading hands. The stock had previously closed at $43.03.
Analysts Set New Price Targets
MBX has been the topic of several research analyst reports. UBS Group reiterated a “buy” rating on shares of MBX Biosciences in a research report on Tuesday, February 24th. Lifesci Capital upgraded MBX Biosciences to a “strong-buy” rating in a report on Tuesday, March 31st. TD Cowen reaffirmed a “buy” rating on shares of MBX Biosciences in a research report on Thursday, March 12th. Wall Street Zen downgraded MBX Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Finally, Barclays upped their price target on MBX Biosciences from $66.00 to $70.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.22.
Get Our Latest Analysis on MBX Biosciences
MBX Biosciences Stock Performance
Hedge Funds Weigh In On MBX Biosciences
A number of hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in MBX Biosciences during the fourth quarter valued at $28,000. Russell Investments Group Ltd. grew its stake in MBX Biosciences by 4,131.4% in the third quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock valued at $26,000 after purchasing an additional 1,446 shares in the last quarter. Royal Bank of Canada increased its position in MBX Biosciences by 59.6% in the 4th quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock worth $49,000 after purchasing an additional 572 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in shares of MBX Biosciences during the 3rd quarter worth about $27,000. Finally, Strs Ohio raised its stake in shares of MBX Biosciences by 128.6% during the 1st quarter. Strs Ohio now owns 1,600 shares of the company’s stock worth $48,000 after purchasing an additional 900 shares in the last quarter.
About MBX Biosciences
We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.
Read More
- Five stocks we like better than MBX Biosciences
- Buy CrowdStrike Before the Stock Split? Here’s the Case
- Investors Are Buying Into Sweetgreen Again—Should They?
- Burlington Is Winning Over Shoppers But Investors Need Patience
- USA Today’s Digital Revival Is Gaining Steam, But With Plenty of Risk
Receive News & Ratings for MBX Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MBX Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
